Every 8-K that Nephros Inc. (NEPH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NEPH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NEPH filings page.
Nephros, Inc. reported strong results for the quarter and six months ended June 30, 2026. Second-quarter net revenue reached a record $6.0 million, up 36% from $4.4 million a year earlier, driven mainly by 27% growth in core programmatic product revenue and nearly tripled service revenue. Net income for the quarter rose to $1.2 million from $0.2 million, and Adjusted EBITDA increased to $1.3 million from $0.4 million.
Quarterly gross margin improved to 67% from 63%, helped by recognition of an approximately $0.6 million tariff refund under the International Emergency Economic Powers Act, recorded as a receivable and reduction of cost of goods sold. For the first half of 2026, net revenue was $11.2 million versus $9.3 million, and net income was $1.3 million versus $0.8 million. As of June 30, 2026, Nephros held about $4.7 million in cash and cash equivalents and remained debt free, with management highlighting its expanding recurring revenue base, growing service platform, and newer product offerings as key growth drivers.
Nephros, Inc. furnished an updated 2026 Corporate Presentation on its website on June 12, 2026, and attached it as Exhibit 99.1 to a current report. The presentation is provided as public information but is designated as “furnished,” meaning it is not treated as formally filed under the securities laws or automatically incorporated into other registration or reporting documents.
Nephros, Inc. reported first-quarter 2026 net revenue of $5.2 million, up 7% from $4.9 million a year earlier, driven by 23% growth in core programmatic product revenue and partially offset by lower emergency response sales. Net income declined to $140,000 from $558,000, and gross margin fell to 57% from 65%, mainly due to U.S. tariffs, a stronger Euro increasing product costs, and a higher mix of lower-margin commercial revenue. Adjusted EBITDA was $206,000, down from $667,000. As of March 31, 2026, Nephros held $4.0 million in cash and cash equivalents, remained debt free, and reported total assets of $13.8 million.
Nephros, Inc. furnished a current report to highlight that it has posted an updated 2026 Corporate Presentation on its corporate website. The presentation is provided as Exhibit 99.1 and is being shared as a Regulation FD disclosure, meaning it is intended to give the market broadly equal access to the same information.
The company notes that the presentation and related disclosure are considered "furnished" rather than "filed" under securities laws, which affects how they may be used in securities law liability and future SEC filings. The report is signed on behalf of Nephros by Chief Financial Officer Judy Krandel.
Nephros, Inc. entered a new long-term license and supply agreement with Medica S.p.A. for ultrafiltration products. The deal gives Nephros an exclusive license, with rights to sublicense, to market, promote, distribute, offer for sale and sell certain Medisulfone-based filtration products in a defined territory, while Nephros grants Medica an exclusive license under its intellectual property to make these products during the term.
In return, Nephros committed to minimum annual aggregate purchases from Medica of €4,976,000, €5,349,000, €5,750,000, €6,000,000 and €6,300,000 for the years 2026, 2027, 2028, 2029 and 2030, respectively. The agreement runs through December 31, 2030, and replaces a prior 2023 license and supply agreement that was terminated when this new contract was signed.
Nephros may terminate the agreement for convenience with 90 days’ written notice, while Medica can terminate for uncured monetary defaults, and either party can terminate for material breaches or specified insolvency events. The contract also includes customary representations, warranties and indemnification obligations.
Nephros, Inc. furnished a press release disclosing its second quarter 2025 financial results and included that press release as Exhibit 99.1 to this Form 8-K. The company explicitly stated the exhibit is furnished, not filed, and therefore is not subject to liability under Section 18 of the Exchange Act nor automatically incorporated by reference into other filings unless expressly stated. The report was signed on behalf of the registrant by the Chief Financial Officer.